Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Investor Day (2022)
38 slides from Fisher & Paykel Healthcare's investor day presentation, 2022
Slide 1: Better Products: An R&D Overview
Better Products: An R&D Overview Andrew Somervell – Vice President Products and Technology
Slide 2: Agenda
Fisher & Paykel Healthcare Investor Day 2022 Agenda General Manager - Respiratory Humidification & 10:00am Welcome Andy Niccol & Vandna Patel Product Development Engineer 10:05am Our Aspiration Lewis Gradon & Lyndal York Managing Director / CEO & CFO Better Products: an R&D 10:25am Andrew Somervell
Slide 3: Our aspiration
Our aspiration Lewis Gradon – Managing Director / CEO Lyndal York - CFO
Slide 4: Our aspiration – prior to COVID-19
Our aspiration – prior to COVID-19 OUR ASPIRATION: Sustainably DOUBLING our constant currency revenue every 5-6 years.
Slide 5: Our aspiration - now
Our aspiration - now OUR ASPIRATION: Sustainably DOUBLING our constant currency revenue every 5-6 years. COVID-19 has accelerated placement of hospital hardware and given us the opportunity to advance our longer-term plans. The image above is an illustration of the company’s long-term growth aspirat
Slide 6: Our aspiration - now
Our aspiration - now OUR ASPIRATION: Sustainably DOUBLING our constant currency revenue every 5-6 years. COVID-19 has accelerated placement of hospital hardware and given us the opportunity to advance our longer-term plans. The image above is an illustration of the company’s long-term growth aspirat
Slide 7: Our aspiration - now
Our aspiration - now OUR ASPIRATION: Sustainably DOUBLING our constant currency revenue every 5-6 years. COVID-19 has accelerated placement of hospital hardware and given us the opportunity to advance our longer-term plans. The image above is an illustration of the company’s long-term growth aspirat
Slide 8: Our aspiration - now
Our aspiration - now OUR ASPIRATION: Sustainably DOUBLING our constant currency revenue every 5-6 years. COVID-19 has accelerated placement of hospital hardware and given us the opportunity to advance our longer-term plans. The image above is an illustration of the company’s long-term growth aspirat
Slide 9: Long term margin targets
Long term margin targets GROSS MARGIN OPERATING (EBIT) MARGIN • Long term gross margin and 70% 40% operating margin targets 35% 60% remain unchanged 30% 50% • Freight rates expected to 25% remain elevated in the near 40% term 20% 30% 15% Accelerated investment in: 20% 10% • R&D – Surgical technologi
Slide 10: Expansion of R&D and manufacturing facilities
Expansion of R&D and manufacturing facilities ~$700m capital expenditure over about five years. This includes: New Zealand • Completion of building 5 • Acquisition of second R&D and manufacturing campus in New Zealand Tijuana, Mexico • Completion of a third manufacturing facility in Mexico Future ma
Slide 11: Better Products: An R&D Overview
Better Products: An R&D Overview Andrew Somervell – Vice President Products and Technology
Slide 12: Better Products: Enabling Clinical Practice Change
Better Products: Enabling Clinical Practice Change Products that: Improve care Drive sustainable and outcomes profitable growth Improve patient Enable treatment outcomes of more patients Improve the Unique delivery of care technologies that deliver customer Lower overall cost valued benefits of trea
Slide 13: A Patient Focused Culture
A Patient Focused Culture • Underlying philosophy of doing what is best for patients − Aligns with long-term needs of all caregivers • Patient care is complex. Complexity provides opportunity • Deep, broad understanding of patient care leads to new insights and solutions • Patient focused, multi-dis
Slide 14: Patient Focused Teams: In-depth Knowledge
Patient Focused Teams: In-depth Knowledge
Slide 15: Enabling our Product Teams
Enabling our Product Teams • Our people: attracting and growing top talent • First-hand access to user environments • Engaging world-leading expertise • Leading prototyping and testing facilities • Co-locating R&D and manufacturing
Slide 16: Airvo 3
Airvo 3 Chris Crone – General Manager Sam Frame – Marketing Manager
Slide 17: Airvo 3
Airvo 3 Designed to facilitate treatment: • of more patients • in more hospital areas • by more types of clinicians
Slide 18: Integrated battery
Integrated battery Current challenge: • Nasal high flow requires a continuous power supply • Continuity of therapy is key Airvo 3 facilitates: • Transfer for diagnostics • Earlier initiation, e.g. prior to admission
Slide 19: Standardised tube kits and interfaces
Standardised tube kits and interfaces Current challenge: • Storage and training burden for new equipment • Treating a wider range of patients Airvo 3 facilitates: • A lower barrier to fleet expansion • Treatment of new patients requiring smaller interfaces
Slide 20: Option for faster reprocessing
Option for faster reprocessing Current challenge: • Downtime of equipment • Differing preference of reprocessing Airvo 3 facilitates: • Greater time treating patients • Flexible options for reprocessing
Slide 21: Clinical user menu and settings
Clinical user menu and settings Current challenge: • Distance between decision makers and patients • Adherence to hospital protocols Airvo 3 facilitates: • Personalised clinical parameters • Alignment between default settings and protocols
Slide 22: OptiO2 - closed loop oxygen control
OptiO2 - closed loop oxygen control Current challenge: • Oxygen can be under or over delivered • Difficult to keep patients within their target range Airvo 3 facilitates: • Use in areas where control matters most • A patient-specific approach
Slide 23: Surgical Humidification
Surgical Humidification Open Abdominal Surgery Winston Fong - Vice President Surgical Technologies
Slide 24: Intro – Laparotomy
Intro – Laparotomy • Patient and open surgical site is exposed to ambient air during laparotomy surgery • Very different to natural physiological state (warm and wet) • Causes evaporation which results in loss of heat and moisture from patient
Slide 25: Clinical problems
Clinical problems Hypothermia Surgical site infection Tissue / Cell damage
Slide 26: SI400 flow visualisation
SI400 flow visualisation Fisher &Paykel HEALTHCARE
Slide 27: Product
Product SI400 Humidified Gas Diffuser Flexible tube Adhesive Backing Mouldable foam head Sterile and Single use Low profile
Slide 28: How could warm, humidified CO2 benefit the patient?
How could warm, humidified CO2 benefit the patient? • Improves temperature • Provides humidity • Reduces risk of SSI CO2 • Improves local wound temperature • Increases tissue oxygenation and perfusion Warm Humidity • Reduces morphological mesothelial damage
Slide 29: Optiflow Anesthesia
Optiflow Anesthesia Winston Fong - Vice President Surgical Technologies
Slide 30: Optiflow nasal high flow therapy
Optiflow nasal high flow therapy Mechanisms of action Respiratory Spontaneously breathing patients support with or at risk of respiratory compromise Reduction of Dynamic positive dead airway space pressure Airway Patient hydration comfort Supplemental oxygen (if required)
Slide 31: What is anesthesia?
What is anesthesia? Analgesia Management of pain Amnesia Controlled state of unconsciousness and loss of memory Paralysis Management of patient movement
Slide 32: General Anesthesia – Clinical complications
General Anesthesia – Clinical complications • Anesthetic agents − Neuro muscular blockade → apnoeic − Loss of muscle tone, airway collapse, atelectasis • Complications include − Airway damage causing: swelling → airway closure − Intubation failure − Desaturation causing anesthetic morbidity and mort
Slide 33: Sedation – Clinical complications
Sedation – Clinical complications • Anesthetic agents − Represses breathing − Causes atelectasis • Complications include − Desaturation: 26-85% of GI Endoscopy cases desaturate1 − Disrupts procedure − Surgery delays − Patient risk/dissatisfaction 1 Nay MA et al. High-flow nasal oxygenation or standa
Slide 34: Optiflow Switch
Optiflow SwitchTM Enables delivery of humidified oxygen in the peri-anesthesia environment User can Switch between bag mask ventilation and Optiflow without needing to remove the nasal interface Reduces the number of steps required to bag mask ventilate a patient vs standard Optiflow nasal high flow
Slide 35: Optiflow Trace
Optiflow TraceTM Sampling of exhaled Secure connection gas from either nose with standard CO2 or mouth* sampling lines Continuous sampling of exhaled CO2 while using Optiflow nasal high flow for oxygenation* *Attention: this applies for flow rates between 5-50L/min.
Slide 36: Systematic and growing clinical evidence
Systematic and growing clinical evidence Hung, 2022 GI endoscopy – demonstrated the efficacy of high flow nasal oxygenation for reducing the risk of hypoxemia in patients under sedation. Guideline 2022 Su, 2022 Bronchoscopy - HFNC may provide consistent Systematic review oxygenation (SpO2>90%) and s
Slide 37: Summary
Summary • Ongoing innovation • Strong and continually growing clinical evidence • Change in clinical practice • Sustainable profitable growth • Extending the use of Optiflow into anesthesia practice
Slide 38: Better Products: An R&D Overview
Better Products: An R&D Overview Andrew Somervell – Vice President Products and Technology